<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416609</url>
  </required_header>
  <id_info>
    <org_study_id>BMed1</org_study_id>
    <nct_id>NCT02416609</nct_id>
  </id_info>
  <brief_title>Low-dose Radiotherapy Plus Chemotherapy With Gem-based Doublets and Stereotactic Radiotherapy for Advanced Pancreatic Cancer</brief_title>
  <acronym>ORCHESTRATE</acronym>
  <official_title>Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With Gem-based Doublets and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Modena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate if low-dose radiotherapy (LDR) can intensify local effect of&#xD;
      a chemotherapy regimen with Gem-based doublets administered sequentially with stereotactic&#xD;
      body radiotherapy (SBRT) and to assess the safety and efficacy of this combined treatment on&#xD;
      patients affected by locally advanced pancreatic adenocarcinoma (LAPC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>defined as the time from the initiation of therapy to the time of first event (local, regional or distant progression or death due to any cause). Patients without any such event at the time of data analysis will be censored at the last date they were known to be event-free. Patients with no tumor assessments after baseline will be censored at day 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity(scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v4.0))</measure>
    <time_frame>every 3 months, up to 1 year</time_frame>
    <description>Acute gastrointestinal toxicity is defined as adverse events occurring &lt;3 months after SBRT; long-term toxicity was defined as those occurring after 3 months. Toxicity is scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>defined as the time from the date of initiation of therapy to date of death due to any cause. Patients who is alive on the date of last follow-up were censored on that date</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gem-based doublets with LDR &amp; sequential SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four Gem-based doublets cycles will be administered concurrent with LDR. If no progression, three fractions of SBRT will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LDR</intervention_name>
    <description>LDR will be delivered during each cycle of Gem-based doublets</description>
    <arm_group_label>Gem-based doublets with LDR &amp; sequential SBRT</arm_group_label>
    <other_name>Low dose radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gem-based doublets</intervention_name>
    <description>4 cycles of Gem-based doublets</description>
    <arm_group_label>Gem-based doublets with LDR &amp; sequential SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered</description>
    <arm_group_label>Gem-based doublets with LDR &amp; sequential SBRT</arm_group_label>
    <other_name>Steretactic body radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
          -  Patients with unresectable disease based on institutional standardized criteria of&#xD;
             unresectability or patients whose disease appeared potentially resectable on axial CT&#xD;
             imaging but were found unresectable at surgery&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. Age ≥ 18&#xD;
&#xD;
          -  Patients with biliary or gastroduodenal obstruction must have drainage or surgical&#xD;
             bypass prior to starting treatment&#xD;
&#xD;
          -  Patients with radiographically assessable disease&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function: -Hemoglobin &gt;10.0 g/dL, absolute&#xD;
             neutrophil count &gt; 1.5 x 10^9/L, platelet count &gt; 100 x 10^9/L. -Aspartate&#xD;
             transaminase (AST or SGOT) and alanine transaminase (ALT or SGPT) should be ≤ 3 x&#xD;
             upper limit of normal (ULN). -Total bilirubin &lt; 2 mg/dL. Patients with elevated&#xD;
             bilirubin due to obstruction should be stented and their bilirubin should decrease to&#xD;
             &lt; 2 mg/dL prior to study entry. - Creatinine &lt; 3 mg/dL or Creatinine clearance &gt; 40&#xD;
             mL/min (calculated according to Cockroft and Gault)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of metastatic disease in the major viscera or peritoneal seeding or ascites&#xD;
&#xD;
          -  Gastric or duodenal obstruction&#xD;
&#xD;
          -  Previous peripheral neuropathy&#xD;
&#xD;
          -  Previous irradiation to the planned field; previous chemotherapy for pancreatic cancer&#xD;
&#xD;
          -  Malignancy (within the past two years) except non-melanomatous skin cancer or&#xD;
             carcinoma in situ of the cervix, uterus, or bladder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Meduri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria Policlinico di Modena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Meduri, MD</last_name>
    <phone>+393388878319</phone>
    <email>brunomeduri@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Meduri, MD</last_name>
      <phone>+393388878319</phone>
      <email>brunomeduri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bruno Meduri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Mantini G, Valentini V, Meduri B, Margaritora S, Balducci M, Micciché F, Nardone L, De Rose F, Cesario A, Larici AR, Maggi F, Calcagni ML, Granone P. Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study. Radiother Oncol. 2012 Nov;105(2):161-6. doi: 10.1016/j.radonc.2012.09.006. Epub 2012 Oct 12.</citation>
    <PMID>23068709</PMID>
  </reference>
  <reference>
    <citation>Regine WF, Hanna N, Garofalo MC, Doyle A, Arnold S, Kataria R, Sims J, Tan M, Mohiuddin M. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):172-7. Epub 2007 Feb 2.</citation>
    <PMID>17276612</PMID>
  </reference>
  <reference>
    <citation>Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):735-42. doi: 10.1016/j.ijrobp.2009.08.046. Epub 2010 Feb 18.</citation>
    <PMID>20171803</PMID>
  </reference>
  <reference>
    <citation>Valentini V, Massaccesi M, Balducci M, Mantini G, Micciché F, Mattiucci GC, Dinapoli N, Meduri B, D'Agostino GR, Salvi G, Nardone L. Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):535-9. doi: 10.1016/j.ijrobp.2009.02.075. Epub 2009 Jun 18.</citation>
    <PMID>19540061</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria di Modena</investigator_affiliation>
    <investigator_full_name>Bruno Meduri</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Locally advanced pancreatic cancer</keyword>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>Chemopotentiator</keyword>
  <keyword>Low dose radiotherapy</keyword>
  <keyword>Hyper-Radiosensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

